Sarepta's stock still up after Tuesday's announcement that its Duchenne drug candidate won't require a FDA AdCom meetingMarket Watch • 03/01/23
Sarepta Therapeutics pops as results top estimates and Morgan Stanley raises share price to $187Proactive Investors • 03/01/23
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene TherapyInvestors Business Daily • 03/01/23
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/01/23
Sarepta stock surges more than 10% as results top expectations, drug given priority reviewMarket Watch • 02/28/23
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 02/28/23
Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship ProgramBusiness Wire • 02/28/23
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial ResultsBusiness Wire • 02/21/23
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4Business Wire • 02/17/23
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product RevenuesGlobeNewsWire • 01/09/23
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy CandidateBusiness Wire • 01/05/23
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/02/22
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene TherapyInvestors Business Daily • 11/28/22
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta's Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular DystrophyGlobeNewsWire • 11/28/22